CJC-1295 (no DAC)
Also called Modified GRF (1-29); Mod GRF 1-29
A short-acting growth-hormone-releasing hormone (GHRH) analogue. The widely quoted human CJC-1295 trial studied the longer-acting DAC version, not this one.
Overview
What it is
Modified GRF (1-29) without the albumin-binding "DAC" (drug affinity complex) group. Without DAC, it clears from the body much faster.
How it works
GHRH signals the pituitary to release growth hormone, which in turn raises IGF-1. The system is tightly regulated by somatostatin and IGF-1 feedback, so more signal is not automatically better. Growth hormone also reduces insulin sensitivity.
What the research shows
Clinical data mainly concern the DAC form (see CJC-1295 DAC). FDA's 2024 review found that clinical references appeared to involve the DAC version and did not establish equivalent evidence for no-DAC substances. Pairing with ipamorelin is based on mechanism, not trials.
Studied for
- Growth hormone releasemechanism, by analogy to related compounds
Safety and regulatory status
Safety and side effects
The FDA flags immune-reaction and impurity concerns for CJC-1295 and has received reports of serious events including fast heart rate and blood-vessel dilation. Shorter action does not automatically mean lower risk. Fatigue or slow training progress alone does not diagnose growth hormone deficiency.
Regulatory status
Not FDA approved. On FDA's list of compounding substances with potential safety risks.
Mixing and dosing reference
Reference information only. Read before using this section.
CJC-1295 NO DAC (5 mg Vial) Dosage Protocol
- Vial
- 5 mg CJC-1295 NO DAC
- Add diluent
- 3 mL
- Concentration
- 1.67 mg/mL
- 1 unit (U-100)
- 16.67 mcg in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous), preferably at bedtime.
- Typical range
- 100–300 mcg once daily (gradual titration).
- Cycle length
- 8–12 weeks; optional extension to 16 weeks.
Standard / Gradual Approach
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg | 9 units (0.09 mL) |
| Weeks 5–6 | 200 mcg | 12 units (0.12 mL) |
| Weeks 7–12 | 250–300 mcg | 15–18 units (0.15–0.18 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 100–150 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated.
- Target: 200–300 mcg daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous), preferably at bedtime.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Administer at bedtime to align with natural nocturnal GH pulses; rotate injection sites.
Storage
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F); freeze only if the exact product instructions or validated stability data support it; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow product-specific use-by instructions; avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
Important notes
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Administer on an empty stomach (fasted for ≥2 hours) to optimize GH response.
Protocol source: PeptideDosages.com
Common questions
Is no DAC better than DAC?
No head-to-head clinical benefit has been established. They are different compounds.
Can DAC trial results be applied to no DAC?
No. The compound and exposure are different.
Does it mimic natural growth hormone pulses?
That claim would need direct measurement for the exact product.
Found in these blends
Related in Performance and Recovery
Sources and further reading (5)
- FDA. CJC-1295-related bulk drug substances: advisory committee briefing, Dec 2024.
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I by CJC-1295 in healthy adults. JCEM, 2006.
- Jetté L, et al. Identification of CJC-1295 as a long-lasting GRF analogue. Endocrinology, 2005.
- Olarescu NC, et al. Normal physiology of growth hormone in adults. Endotext, 2025.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).
Laboratory research material: CJC-1295 No DAC Research Use Only